Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Can-Fite BioPharma reported positive results from its Phase 2a trial of Namodenoson in advanced pancreatic cancer patients. The study showed preliminary evidence of clinical activity with stable disease in over 30% of evaluable patients, including prolonged treatment of one patient beyond 16 months. Namodenoson demonstrated a favorable safety profi…